Apnimed, Inc.
APMD evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for APMD—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · APMD
Apnimed, Inc. is a late-stage clinical pharmaceutical company developing Oxnimbi, an oral therapy for obstructive sleep apnea (OSA), with an NDA submitted to the FDA in April 2026 and a joint venture with Shionogi (SASS) for novel sleep-disorder therapies.
Key risk: Going concern risk
Market Cap
$1.18B
Cash Runway
—
Lead Asset
—
Next Catalyst
—
Tracking 1 clinical trial for Apnimed, Inc..
Apnimed, Inc. is a late-stage clinical pharmaceutical company developing Oxnimbi, an oral therapy for obstructive sleep apnea (OSA), with an NDA submitted to the FDA in April 2026 and a joint venture with Shionogi (SASS) for novel sleep-disorder therapies.
- Apnimed has submitted an NDA for Oxnimbi for the treatment of OSA in April 2026, with an expected FDA review cycle of 10 months [sec · filed 2026-07-10].
- Oxnimbi was generally well-tolerated in Phase 3 trials (LunAIRo and SynAIRgy), with no drug-related serious adverse events reported [sec · filed 2026-07-10].
- Cash and cash equivalents were $46.9 million as of March 31, 2026, which management expects will not be sufficient to fund operations for 12 months from the issuance of the financial statements [sec · filed 2026-07-10].
- The company has incurred significant operating losses since inception and expects to continue generating losses for the foreseeable future [sec · filed 2026-07-10].
- Apnimed entered into a joint venture with Shionogi (SASS) in November 2023 to develop therapies for OSA and other sleep breathing disorders, with discovery programs initiated in 2024 and continued in 2025 [sec · filed 2026-07-10].
What works
- Oxnimbi has completed Phase 3 trials with a favorable safety profile (no drug-related SAEs) and an NDA has been submitted, positioning the company for potential FDA approval [sec · filed 2026-07-10].
- The joint venture with Shionogi (SASS) provides a pipeline for next-generation sleep-disorder therapies beyond Oxnimbi [sec · filed 2026-07-10].
What to weigh
- The company has substantial doubt about its ability to continue as a going concern, with cash of $46.9 million as of March 31, 2026 insufficient to fund operations for the next 12 months [sec · filed 2026-07-10].
- Apnimed has no approved products and has never generated revenue from product sales; the earliest potential revenue from Oxnimbi, if approved, is 2027 [sec · filed 2026-07-10].
- The company faces significant regulatory and commercial risks, including the possibility that the FDA may issue a complete response letter deeming the NDA unapprovable [sec · filed 2026-07-10].
From the filings
Quoted directly from source documents.
Oxnimbi was well-tolerated in Phase 3 trials with no drug-related SAEs
“Oxnimbi was generally well-tolerated, with AEs predominantly mild across both trials, with no drug-related SAEs in the Oxnimbi group reported in either LunAIRo or SynAIRgy.”
SEC filings · July 10, 2026
Cash position as of March 31, 2026 is $46.9 million and is insufficient for 12 months
“We expect that our cash and cash equivalents of $46.9 million as of March 31, 2026 in addition to the cash received through the transactions consummated in the year ending December 31, 2026 and described within Note 16 to our unaudited condensed consolidated financial statements will not be sufficient to fund our operating expenses and capital expenditure requirements for 12 months from the date our unaudited quarterly condensed consolidated financial statements are issued.”
SEC filings · July 10, 2026
Substantial doubt about going concern
“There is substantial doubt about our ability to continue as a going concern.”
SEC filings · July 10, 2026
NDA submitted in April 2026 with 10-month FDA review cycle expected
“We believe the FDA review cycle will be 10-months from our NDA submission in April 2026 although the duration of the review may vary based on various factors.”
SEC filings · July 10, 2026
Risks & what to watch (4)›
Key risks
- Going concern risk — Substantial doubt about ability to continue as a going concern; cash of $46.9M as of March 31, 2026 insufficient for 12 months [sec · filed 2026-07-10].
- No approved products or revenue — No product revenue to date; earliest potential revenue from Oxnimbi is 2027 if approved [sec · filed 2026-07-10].
- Regulatory approval uncertainty — FDA may issue a complete response letter deeming the NDA unapprovable; additional trials may be required [sec · filed 2026-07-10].
- Dependence on Oxnimbi — Company's prospects rely heavily on successful development and commercialization of a single product candidate, Oxnimbi [sec · filed 2026-07-10].
What to watch
- FDA decision on Oxnimbi NDA, expected within 10 months from April 2026 submission [sec · filed 2026-07-10].
- Company's ability to raise additional capital to fund operations beyond the current cash runway [sec · filed 2026-07-10].
- Progress of SASS joint venture discovery and development programs for novel OSA therapies [sec · filed 2026-07-10].
Sources: SEC filings · Generated August 15, 2026 · How we verify sources →
Run Apnimed, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Apnimed, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Regulatory
Financials
Frequently asked questions
What is the AI investment thesis for Apnimed, Inc.?
Apnimed, Inc. is a late-stage clinical pharmaceutical company developing Oxnimbi, an oral therapy for obstructive sleep apnea (OSA), with an NDA submitted to the FDA in April 2026 and a joint venture with Shionogi (SASS) for novel sleep-disorder therapies.
Who is the CEO of Apnimed, Inc.?
Mr. Kevin Robert Lind is the chief executive officer of Apnimed, Inc. (APMD).
Where is Apnimed, Inc. headquartered?
Apnimed, Inc. (APMD) is headquartered in Cambridge, MA, United States.
What therapeutic areas does Apnimed, Inc. focus on?
Apnimed, Inc. develops therapies across Oncology, Respiratory.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.